Skip to content

Exploratory Study of Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants Rivaroxaban in Patients with Left Ventricular Thrombus

Exploratory Study of Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants Rivaroxaban in Patients with Left Ventricular Thrombus

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000038963
Enrollment
Unknown
Registered
2020-10-10
Start date
2020-10-13
Completion date
Unknown
Last updated
2021-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Left Ventricular Thrombus

Interventions

Single-arm:Rivaroxaban

Sponsors

Fuwai Hospital, Chinese Academy of Medical Sciences & Pecking Union Medical College
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients over 18 years old; 2. Patients with left ventricular thrombus newly found by body surface ultrasound less than or equal to 3 months before selection, with no limitation on basic diseases; 3. Patients who received standard anticoagulant therapy for less than 4 weeks before enrollment did not use antiplatelet drugs or only used single antiplatelet drugs; 4. The patients voluntarily joined the study and signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with contraindications to rivaroxaban anticoagulation therapy; 2. Patients with a history of acute pulmonary embolism or deep venous thrombosis within a week need intensive anticoagulant therapy; 3. Patients with history of hemorrhagic stroke within one week; 4. Patients with cardiac benign and malignant tumors; 5. Aspirin and P2Y12 receptor antagonists should be kept; 6. In patients with severe hepatic and renal insufficiency, alanine aminotransferase > 3 times the upper limit and total bilirubin > 2 times the upper limit, creatinine clearance rate < 15ml / min / 1.73m2; 7. The patient's history of intracerebral hemorrhage and active hemorrhage was 8 months; 8. Patients with hematological diseases, hemoglobin < 100g / L, platelet < 80 x 10^9 / L; 9. Women with pregnancy status, planned pregnancy and lactation period; 10. Patients with life expectancy less than 1 year; 11. Patients enrolled in other clinical studies; 12. Other situations considered unsuitable by the researcher. Conclusion: anticoagulant therapy can be given to patients with left ventricular thrombosis combined with hemorrhagic stroke = 4 weeks or recent ischemic stroke / TIA according to the specific situation.

Design outcomes

Primary

MeasureTime frame
the left ventricular thrombus resolution rate at 12 weeks;

Secondary

MeasureTime frame
the left ventricular thrombus resolution or reduction rate at 6 weeks;the left ventricular thrombus resolution or reduction rate at 12 weeks;

Countries

China

Contacts

Public ContactLiang Yan

Fuwai Hospital, Chinese Academy of Medical Sciences & Pecking Union Medical College

fwliangyan2016@163.com+86 15699870217

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026